查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2048111

斯特格氏黃斑失養症治療市場 - 全球產業規模、佔有率、趨勢、機會、預測：按藥物類型、分銷管道、地區和競爭格局分類，2021-2031 年

Stargardt Disease Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 177 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球斯特格氏黃斑失養症治療市場預計將從 2025 年的 2.1221 億美元大幅成長至 2031 年的 3.2842 億美元，複合年成長率為 7.55%。

該市場涵蓋多種療法，包括藥物、基因編輯技術和細胞再生醫學，所有這些療法都旨在糾正導致此類青少年黃斑部病變的基因缺陷。推動這一市場成長的主要因素是對有效治療方法的迫切需求，以及孤兒藥認定所提供的獎勵，該認定鼓勵製藥公司投資於罕見疾病治療方法。此外，基因篩檢技術的進步使得患者能夠更早被診斷出來，並能更快地招募受試者參與臨床試驗。病患權益倡導組織的大力資助也發揮了重要作用，例如，美國防盲基金會（Foundation Fighting Blindness）在2024年津貼1,980萬美元用於視網膜退化性疾病的研究。

市場概覽
預測期 2027-2031
市場規模：2025年 2.1221億美元
市場規模：2031年 3.2842億美元
複合年成長率：2026-2031年 7.55%
成長最快的細分市場 LBS-008
最大的市場 北美洲

然而，開發這些治療方法仍面臨許多挑戰。其中之一是目標基因ABCA4固有的生物學複雜性。其龐大的編碼序列超出了基因治療中常用病毒載體的容量，構成了一項重大的技術障礙。這項限制使得將正常基因拷貝高效遞送至視網膜細胞變得困難，成為該領域治療方法發展的主要阻礙。

市場促進因素

基因治療和基因組編輯技術的持續進步是推動這一市場發展的關鍵因素。這些創新對於克服傳統病毒載體負載容量的限制至關重要，而載藥量限制先前一直阻礙ABCA4的有效遞送。包括光遺傳學平台和非病毒遞送方法在內的新方法，使研究人員能夠針對斯特格氏黃斑失養症的遺傳因素，繞過功能異常的光感受器來恢復視力。這些技術的成熟體現在監管機構的支持上，使得治療方法能夠快速推進到臨床試驗的後期階段。一個典型的例子是，FDA於2024年9月核准了Nanoscope Therapeutics公司MCO-010的主要臨床試驗方案，使其得以進入III期臨床試驗。

另一個驅動力是眼科生物技術和研發領域投資的不斷成長。這種資金投入對於資助成本高昂的後期臨床試驗以及探索更廣泛的治療標靶至關重要。資金的湧入將使有前景的候選藥物能夠從早期概念驗證快速推進到商業化階段，從而降低孤兒藥研發中常見的高失敗率。例如，2024年11月，Belite Bio宣布已透過行使認股權證籌集了約2,875萬美元，用於支持其全球臨床營運。同時，2024年11月，對抗失明基金會進一步擴大了其研究框架，授予35項新的津貼，並專注於視網膜退化性疾病。

市場挑戰

斯特格氏黃斑失養症治療藥物全球市場擴張的主要障礙在於ABCA4基因複雜的生物學特性，尤其是其龐大的編碼序列。這種龐大的序列長度超過了傳統腺結合病毒（AAV）載體的包裝能力，而AAV載體是眼內基因轉殖的標準載體。因此，研發人員不得不採用更複雜的雙載體系統或替代的非病毒載體，而這些方法本身就存在顯著的技術風險。與更簡單的單載體療法相比，這些更複雜的遞送方法往往轉導效率更低、穩定性更差，導致臨床前開發失敗率更高，監管核准流程也更長。

這些技術壁壘透過增加研發成本直接阻礙市場成長，從而限制了擁有足夠財力支持長期臨床專案的生物技術公司數量。克服這些生物工程挑戰所需的大量資本投入，造成了一種限制性環境，只有資金充足的專案才能推進，最終阻礙了整個治療藥物開發平臺的發展。外部資金對於降低這些早期技術相關的風險仍然至關重要，例如，黃斑學會2024年對黃斑研究的投資超過160萬英鎊。在開發出更有效、更有效率的基因遞送方法之前，基因療法的商業化前景仍然有限。

市場趨勢

口服視覺循環調變器的興起是一個顯著的趨勢。這代表著治療方式朝向非侵入性方向轉變，與複雜的基因外科手術療法截然不同。這些小分子藥物旨在系統性地阻止有害的維生素A代謝物（如脂褐素和類視色素）的積累，這些代謝物是導致斯特格氏黃斑失養症視網膜萎縮的主要因素。透過口服調節視覺循環，這種方法避免了將基因遞送至視網膜的技術難題以及載體免疫抗原性相關的問題。近期的後期臨床試驗已證實了此方法的療效。 2025年12月，Belite Bio公司宣布，其口服在臨床實驗藥物Tinlarebant在青少年患者中，與安慰劑相比，顯著降低了視網膜病變進展率36%。

同時，人們對開發不依賴突變的基因療法也越來越感興趣。這些治療方法旨在利用修飾基因來調節視網膜穩態，而不是嘗試完全取代基因。此策略透過引入影響氧化壓力和發炎相關路徑的核激素受體，有效應對了斯特格氏黃斑失養症的遺傳多樣性，為各種ABCA4突變提供了廣泛的治療益處。這種機制為突變特異性療法提供了一個切實可行的替代方案，後者通常會受到目標基因龐大編碼序列的限制。例如，Ocugen公司於2025年8月報告稱，在其I/II期GARDian臨床試驗中，其修飾基因療法OCU410ST使接受治療的眼睛的疾病進展速度比未接受治療的眼睛減緩了48%。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：斯特格氏黃斑失養症治療藥物的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 藥物類型（LBS-008，Emixstat）
    • 分銷通路（醫院藥局、零售藥局、網路藥局）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美斯特格氏黃斑失養症治療藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲斯特格氏黃斑失養症治療藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區斯特格氏黃斑失養症治療藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲斯特格氏黃斑失養症治療藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美斯特格氏黃斑失養症治療藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球斯特格氏黃斑失養症治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Kubota Pharmaceutical Holdings Co Ltd
  • IVERIC bio Inc
  • Sanofi SA
  • Alkeus Pharmaceuticals Inc
  • Astellas Pharma Inc
  • Cha Biotech Co Ltd/Old
  • reVision Therapeutics, Inc.
  • Biogen Inc
  • F Hoffmann-La Roche AG
  • Ocugen Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 18728

The global market for Stargardt disease therapeutics is projected to expand significantly, rising from USD 212.21 Million in 2025 to USD 328.42 Million by 2031, demonstrating a compound annual growth rate of 7.55%. This market includes a diverse array of treatments, such as pharmacological agents, gene editing technologies, and cell-based regenerative therapies, all aimed at correcting the genetic defects causing this form of juvenile macular degeneration. Key drivers for this growth are the urgent demand for effective treatments and the incentives provided by orphan drug designations, which encourage pharmaceutical companies to invest in therapies for rare diseases. Additionally, enhanced genetic screening methods aid in earlier patient diagnosis and faster recruitment for clinical trials, with strong financial backing from advocacy groups, exemplified by the Foundation Fighting Blindness's $19.8 million in research grants in 2024 for retinal degenerative diseases.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 212.21 Million
Market Size 2031USD 328.42 Million
CAGR 2026-20317.55%
Fastest Growing SegmentLBS-008
Largest MarketNorth America

However, the development of these therapies is challenged by the inherent biological complexity of the target gene, ABCA4. Its extensive coding sequence presents a substantial technical hurdle, as it surpasses the capacity of conventional viral vectors used in gene therapy. This limitation complicates the efficient delivery of healthy gene copies to the retinal cells, posing a notable barrier to therapeutic advancement in the sector.

Market Driver

The market is significantly propelled by continuous advancements in gene therapy and genome editing technologies. These innovations are crucial for overcoming the historical payload constraints of traditional viral vectors, which previously impeded the effective delivery of ABCA4. New approaches, including optogenetic platforms and non-viral delivery methods, are now enabling researchers to address the genetic origins of Stargardt disease or bypass compromised photoreceptors to restore vision. The maturation of these technologies is evident through regulatory support, which is expediting therapies into advanced clinical stages, as highlighted by the FDA's endorsement in September 2024 of Nanoscope Therapeutics' pivotal trial design for MCO-010, allowing its progression to a Phase 3 study.

A secondary driving force is the escalating investment in ophthalmic biotechnology and research. This financial commitment is vital for funding the costly late-stage clinical trials and for exploring a wider range of therapeutic targets. This influx of capital facilitates the rapid progression of promising drug candidates from early proof-of-concept stages to commercialization, thereby reducing the high failure rates often seen in orphan drug development. For instance, Belite Bio reported securing around $28.75 million in November 2024 from warrant exercises to support its global clinical operations, while the Foundation Fighting Blindness further expanded the research landscape by awarding 35 new grants for retinal degenerative conditions in November 2024.

Market Challenge

The main impediment to the expansion of the Global Stargardt Disease Therapeutics Market is the intricate biological nature of the ABCA4 gene, particularly its large coding sequence. This extensive size exceeds the packaging capabilities of conventional adeno-associated viral (AAV) vectors, which are the standard for gene delivery in the eye. Consequently, developers are compelled to employ more intricate dual-vector systems or alternative non-viral carriers, which inherently introduce substantial technical risks. These more complex delivery approaches typically exhibit reduced transduction efficiency and compromised stability compared to simpler, single-vector therapies, leading to elevated failure rates during preclinical development and prolonging the regulatory approval process.

This technical hurdle directly restricts market growth by increasing research and development expenditures, thereby limiting the number of biotechnology companies that can afford to sustain long-term clinical programs. The considerable capital investment required to surmount these bioengineering challenges fosters a constrained environment where only adequately financed initiatives can advance, thus impeding the overall therapeutic pipeline. External funding remains critical for mitigating the risks associated with these early-stage technologies, as evidenced by the Macular Society's investment of over £1.6 million in 2024 for macular research. Until a more effective and streamlined gene delivery method is developed, the market will continue to encounter limited commercialization prospects for genetic treatments.

Market Trends

A significant trend is the rise of oral visual cycle modulators, marking a shift toward non-invasive pharmacological treatments, distinct from intricate surgical gene therapies. These small molecule drugs are formulated to systemically prevent the buildup of harmful vitamin A byproducts, like lipofuscin and bisretinoids, which are key contributors to retinal atrophy in Stargardt disease. By orally regulating the visual cycle, this method avoids the technical difficulties associated with retinal transfection and issues related to vector immunogenicity. The therapeutic promise of this approach was recently confirmed in late-stage trials, with Belite Bio announcing in December 2025 that its oral investigational drug, Tinlarebant, achieved a statistically significant 36% reduction in retinal lesion growth rate compared to placebo in adolescent patients.

Simultaneously, there is increasing interest in the development of mutation-agnostic gene therapies. These therapies aim to regulate retinal homeostasis by using modifier genes, rather than attempting a complete gene replacement. This strategy effectively addresses the genetic diversity of Stargardt disease by delivering nuclear hormone receptors that influence pathways involved in oxidative stress and inflammation, offering a broad therapeutic advantage across various ABCA4 mutations. This mechanism presents a practical alternative to mutation-specific approaches, which are often hindered by the substantial coding sequence of the target gene. For instance, Ocugen reported in August 2025 that its modifier gene therapy, OCU410ST, showed a 48% slower lesion growth in treated eyes compared to untreated eyes during its Phase 1/2 GARDian clinical trial.

Key Market Players

  • Kubota Pharmaceutical Holdings Co Ltd
  • IVERIC bio Inc
  • Sanofi SA
  • Alkeus Pharmaceuticals Inc
  • Astellas Pharma Inc
  • Cha Biotech Co Ltd/Old
  • reVision Therapeutics, Inc.
  • Biogen Inc
  • F Hoffmann-La Roche AG
  • Ocugen Inc

Report Scope

In this report, the Global Stargardt Disease Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Stargardt Disease Therapeutics Market, By Drug Type

  • LBS-008
  • Emixustat

Stargardt Disease Therapeutics Market, By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Stargardt Disease Therapeutics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Stargardt Disease Therapeutics Market.

Available Customizations:

Global Stargardt Disease Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Stargardt Disease Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Type (LBS-008, Emixustat)
    • 5.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Stargardt Disease Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Type
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Stargardt Disease Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Type
        • 6.3.1.2.2. By Distribution Channel
    • 6.3.2. Canada Stargardt Disease Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Type
        • 6.3.2.2.2. By Distribution Channel
    • 6.3.3. Mexico Stargardt Disease Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Type
        • 6.3.3.2.2. By Distribution Channel

7. Europe Stargardt Disease Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Type
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Stargardt Disease Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Type
        • 7.3.1.2.2. By Distribution Channel
    • 7.3.2. France Stargardt Disease Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Type
        • 7.3.2.2.2. By Distribution Channel
    • 7.3.3. United Kingdom Stargardt Disease Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Type
        • 7.3.3.2.2. By Distribution Channel
    • 7.3.4. Italy Stargardt Disease Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Type
        • 7.3.4.2.2. By Distribution Channel
    • 7.3.5. Spain Stargardt Disease Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Type
        • 7.3.5.2.2. By Distribution Channel

8. Asia Pacific Stargardt Disease Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Type
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Stargardt Disease Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Type
        • 8.3.1.2.2. By Distribution Channel
    • 8.3.2. India Stargardt Disease Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Type
        • 8.3.2.2.2. By Distribution Channel
    • 8.3.3. Japan Stargardt Disease Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Type
        • 8.3.3.2.2. By Distribution Channel
    • 8.3.4. South Korea Stargardt Disease Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Type
        • 8.3.4.2.2. By Distribution Channel
    • 8.3.5. Australia Stargardt Disease Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Type
        • 8.3.5.2.2. By Distribution Channel

9. Middle East & Africa Stargardt Disease Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Type
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Stargardt Disease Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Type
        • 9.3.1.2.2. By Distribution Channel
    • 9.3.2. UAE Stargardt Disease Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Type
        • 9.3.2.2.2. By Distribution Channel
    • 9.3.3. South Africa Stargardt Disease Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Type
        • 9.3.3.2.2. By Distribution Channel

10. South America Stargardt Disease Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Type
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Stargardt Disease Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Type
        • 10.3.1.2.2. By Distribution Channel
    • 10.3.2. Colombia Stargardt Disease Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Type
        • 10.3.2.2.2. By Distribution Channel
    • 10.3.3. Argentina Stargardt Disease Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Type
        • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Stargardt Disease Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Kubota Pharmaceutical Holdings Co Ltd
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. IVERIC bio Inc
  • 15.3. Sanofi SA
  • 15.4. Alkeus Pharmaceuticals Inc
  • 15.5. Astellas Pharma Inc
  • 15.6. Cha Biotech Co Ltd/Old
  • 15.7. reVision Therapeutics, Inc.
  • 15.8. Biogen Inc
  • 15.9. F Hoffmann-La Roche AG
  • 15.10. Ocugen Inc

16. Strategic Recommendations

17. About Us & Disclaimer